These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22301702)

  • 1. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing.
    Djordjevic B; Hennessy BT; Li J; Barkoh BA; Luthra R; Mills GB; Broaddus RR
    Mod Pathol; 2012 May; 25(5):699-708. PubMed ID: 22301702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas.
    Djordjevic B; Barkoh BA; Luthra R; Broaddus RR
    Mod Pathol; 2013 Oct; 26(10):1401-12. PubMed ID: 23599155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies.
    Wang L; Piskorz A; Bosse T; Jimenez-Linan M; Rous B; Gilks CB; Brenton JD; Singh N; Köbel M
    Int J Gynecol Pathol; 2022 Jan; 41(1):12-19. PubMed ID: 33720084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
    Westin SN; Ju Z; Broaddus RR; Krakstad C; Li J; Pal N; Lu KH; Coleman RL; Hennessy BT; Klempner SJ; Werner HM; Salvesen HB; Cantley LC; Mills GB; Myers AP
    Mol Oncol; 2015 Oct; 9(8):1694-703. PubMed ID: 26045339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas.
    Wappenschmidt B; Wardelmann E; Gehrig A; Schöndorf T; Maass N; Bonatz G; Gassel AM; Pietsch T; Mallmann P; Weber BH; Schmutzler RK
    Hum Pathol; 2004 Oct; 35(10):1260-5. PubMed ID: 15492994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
    Catasus L; Gallardo A; Cuatrecasas M; Prat J
    Mod Pathol; 2009 Apr; 22(4):522-9. PubMed ID: 19234438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
    Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
    Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
    Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
    Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
    McConechy MK; Ding J; Senz J; Yang W; Melnyk N; Tone AA; Prentice LM; Wiegand KC; McAlpine JN; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    Mod Pathol; 2014 Jan; 27(1):128-34. PubMed ID: 23765252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium.
    Erkanli S; Kayaselcuk F; Kuscu E; Bagis T; Bolat F; Haberal A; Demirhan B
    Int J Gynecol Cancer; 2006; 16(3):1412-8. PubMed ID: 16803539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
    An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
    Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of mutation profiles to refine the classification of endometrial carcinomas.
    McConechy MK; Ding J; Cheang MC; Wiegand K; Senz J; Tone A; Yang W; Prentice L; Tse K; Zeng T; McDonald H; Schmidt AP; Mutch DG; McAlpine JN; Hirst M; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    J Pathol; 2012 Sep; 228(1):20-30. PubMed ID: 22653804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible.
    Garg K; Broaddus RR; Soslow RA; Urbauer DL; Levine DA; Djordjevic B
    Int J Gynecol Pathol; 2012 Jan; 31(1):48-56. PubMed ID: 22123723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlations of p-AKT with PTEN, P53, HER-2 expressions in endometrial carcinoma and their relationship with patient survival].
    Zhang XM; Liang Y; Dong Y; Zhang Y; Wang Y; Meng YT; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Feb; 44(1):135-41. PubMed ID: 22353917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
    Dedes KJ; Wetterskog D; Mendes-Pereira AM; Natrajan R; Lambros MB; Geyer FC; Vatcheva R; Savage K; Mackay A; Lord CJ; Ashworth A; Reis-Filho JS
    Sci Transl Med; 2010 Oct; 2(53):53ra75. PubMed ID: 20944090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma.
    Inaba F; Kawamata H; Teramoto T; Fukasawa I; Inaba N; Fujimori T
    Oncol Rep; 2005 Jan; 13(1):17-24. PubMed ID: 15583796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Expression and Clinical Significance of DNA Methyltransferase 3B (DNMT3B), Phosphatase and Tensin Homolog (PTEN) and Human MutL Homologs 1 (hMLH1) in Endometrial Carcinomas.
    Li W; Wang Y; Fang X; Zhou M; Li Y; Dong Y; Wang R
    Med Sci Monit; 2017 Feb; 23():938-947. PubMed ID: 28220037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
    Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.